Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Actavis

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs.

Actavis

EU starts investigation of Aspen's cancer drug pricing

EU starts investigation of Aspen's cancer drug pricing launched an investigation into the pricing of Actavis' hydrocortisone tablets.

Change at the top at Teva as Vigodman departs

Change at the top at Teva as Vigodman departs is struggling to absorb an Actavis generics unit it bought for around $40bn last year. ... Peterburg said the "immediate focus" is "realising the cost synergies and strategic benefits of the Actavis generics acquisition".

Teva Generics Europe appoints president and CEO

Teva Generics Europe appoints president and CEO Daniell has over 25 years of experience working at Teva and served as the company's chief integration officer, leading the integration programme to bring Actavis and Teva together.

Deal Watch November 2016

Deal Watch November 2016 3.63. 2015. 23.30 (a). 2014. 98.63 (b). 2013. 20.98. (a) excludes $160bn Pfizer bid for Actavis/Allergan which was ultimately terminated. ... b) includes Actavis' $66bn acquisition of Allergan. But there may be some big deals in the wings.

Deal Watch October 2016

Deal Watch October 2016 In this scenario Actavis (Allergan) put at risk less than 17% of the total consideration rather than the 33% Astellas has paid. ... Teva (IS). Intas (IN). Asset Acquisition. Former Actavis generics business and factory in UK and Ireland.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Evoke Kyne

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...